Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $100.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target lifted by Citigroup from $60.00 to $100.00 in a research note released on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Jefferies Financial Group boosted their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 23rd. Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Finally, Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $87.38.

Kiniksa Pharmaceuticals International Trading Down 4.9%

Shares of Kiniksa Pharmaceuticals International stock opened at $74.34 on Wednesday. The company’s 50-day moving average price is $59.04 and its 200-day moving average price is $51.13. Kiniksa Pharmaceuticals International has a 12-month low of $29.90 and a 12-month high of $82.94. The company has a market cap of $5.72 billion, a price-to-earnings ratio of 76.64 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The business had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International will post 1.38 earnings per share for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the transaction, the director owned 11,672 shares in the company, valued at approximately $950,450.96. The trade was a 23.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 51.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Rubric Capital Management LP boosted its position in shares of Kiniksa Pharmaceuticals International by 2.3% during the third quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after buying an additional 90,194 shares during the last quarter. Vanguard Group Inc. increased its holdings in Kiniksa Pharmaceuticals International by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock valued at $128,409,000 after buying an additional 49,802 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Kiniksa Pharmaceuticals International by 45.3% during the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after buying an additional 332,846 shares during the last quarter. Qube Research & Technologies Ltd raised its position in Kiniksa Pharmaceuticals International by 277.8% in the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after acquiring an additional 653,236 shares during the period. Finally, Millennium Management LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after acquiring an additional 67,452 shares during the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.